Interferon beta, progressive MS, and brain atrophy

摘要

Progressive brain and spinal-cord atrophy in multiple sclerosis (MS) correlates poorly with demyelination, which is traditionally used as the marker of clinical relapses. The therapeutic effect of interferon beta, the most widely prescribed therapy in relapsing MS, deserves our attention after the recent publications of the North American trial in secondary progressive MS1 and brain volume studies in patients presenting with clinically isolated syndromes.